**Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients**

Marco Basset,1,2 Paolo Milani,1,2 Virginia Valeria Ferretti,3 Mario Nuvolone,1,2 Andrea Foli,1,2 Francesca Benigna,1,2 Martina Nanci,1,2 Margherita Bozzola,1,2 Jessica Ripepi,1,2 Melania Sesta,1,2 Francesca Russo,4 Tiziana Bosoni,5 Catherine Klersy,3 Riccardo Albertini,5 Giampaolo Merlini,1,2 Giovanni Palladini1,2

Affiliations: 1Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Matteo , Pavia , Italy; 2Department of Molecular Medicine , University of Pavia , Pavia , Italy; 3Clinical Epidemiology and Biometry Service, Fondazione IRCCS Policlinico San Matteo; 4Department of Public Health, Experimental and Forensic Medicine, University of Pavia, via Forlanini, 12, 27100, Pavia, Italy; 5Laboratory of Clinical Chemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.

**Corresponding author:**

Giovanni Palladini, M.D., Ph.D.

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo

Viale Golgi, 19 – 27100 Pavia, Italy

e-mail: giovanni.palladini@unipv.it

**Supplemental Table 1. Characteristics of patients in the testing and validation cohorts**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Testing cohort****354 pts.****N (%) – median (IQR)** | **Validation cohort****177 pts.****N (%) – median (IQR)** | **P** |
| Age, years | 66 (56-73) | 66 (59-73) | 0.560 |
| Sex, male | 207 (58%) | 97 (55%) | 0.475 |
| Organ involvement Heart Kidney  Liver ST PNS  ANS | 263 (74%)225 (64%)31 (9%)54 (15%)24 (7%)20 (6%) | 130 (73%)103 (58%)15 (8%)38 (21%)11 (3%)6 (2%) | 0.9120.2690.9990.0990.9650.357 |
| Mayo Stage  I II IIIa IIIb | N=32145 (14%)130 (40%)86 (27%)60 (17%) | N=16126 (16%)55 (34%)46 (26%)34 (19%) | 0.6210.2100.7560.604 |
| Renal staging I II III | 163 (46%)142 (40%)50 (14%) | 73 (41%)79 (45%)25 (14%) | 0.3380.3670.999 |
| Proteinuria, g/24h | 1.29 (0.24-5.86) | 1.50 (0.21-5.41) | 0.998 |
| eGFR, mL/min x 1.73 m2 | 60 (35-87) | 58 (35-81) | 0.349 |
| UACR, mg/g | 1184 (95.59-5893) | 1230 (73.83-6172.50) | 0.931 |
| Monoclonal component IgG IgA  IgM IgD  FLC | 126 (33%)38 (14%)23 (6%)2 (1%)163 (46%) | 58 (39%)22 (7%)5 (3%)1 (1%)88 (50%) | 0.5850.6560.1050.9990.480 |
| LC isotype Kappa Lambda | 68 (19%)286 (81%) | 44 (25%)133 (75%) | 0.1660.166 |
| dFLC, mg/L | 169 (69-404) | 174 (62-470) | 0.716 |
| dFLC <50 mg/L | 63 (18%) | 41 (23%) | 0.178 |
| BMPC, % | 10 (7-15) | 10 (6-19) | 0.283 |
| Treatment  CyBorD BMDex BDex MDex  IMiDs Rituximab other\* | 180 (51%)55 (16%)17 (5%)46 (13%)22 (6%)13 (4%)10 (3%) | 94 (53%)37 (21%)5 (3%)18 (10%)6 (3%)7 (4%)- | 0.6900.1580.3910.4250.2390.9990.077 |

\* High dose dexamethasone in 8, autologous stem cell transplant in 1 and daratumumab, bortezomib and dexamethasone in 1 case, respectively.

ST, soft tissues; PNS, peripheral nervous system; ANS, autonomic nervous system; eGFR, estimated glomerular filtration rate; UACR, urinary albumin to creatinine ratio; FLC, free light chain; LC, light chains; dFLC, difference between involved and uninvolved free light chains; BMPC, bone marrow plasma cells; CyBorD, cyclophosphamide, bortezomib and dexamethasone; BMDex, bortezomib, melphalan and dexamethasone; BDex, bortezomib and dexamethasone; MDex, melphalan and dexamethasone; IMiDs, immunomodulatory drugs.